Looking for representation in the Belviq lawsuit? Our experience, expertise, and resources make Hollis Law the ideal partner.
Belviq is a medication prescribed to help patients lose weight. Belviq works by targeting the hunger receptors in the brain and makes an individual feel full sooner while reducing appetite. The FDA approved Belviq in 2012 to be used by obese or overweight adults in conjunction with a reduced calorie diet and exercise to increase weight loss. Belviq is available in a tablet (Belviq) and an extended-release tablet (Belviq XR). Belviq is manufactured by Eisai Inc., a subsidiary of a Tokyo based pharmaceutical company.
If you’ve been affected by this drug, contact us to learn how we can represent you in the Elmiron lawsuit.
Call the Hollis Law Firm at 1-800-701-3672 if you or a loved one has taken this medication since 2013 and developed cancer. All calls and case evaluations are free and carry no obligation. The Hollis Law Firm works on cases on a contingent fee basis, which means we don’t get paid if you don’t get paid. Call 1-800-701-3672 to speak to one of our trained intake specialist so that your potential cancer claim can be reviewed by an attorney at the Hollis Law Firm. The injuries and damages caused by contaminated products will not be uniform; therefore, claims will need to proceed on an individual basis and not as part of a class action.
Prior to Belviq’s approval, the FDA feared that Belviq may cause heart -elated complications similar to prior weight loss drugs like fenfluramine/phentermine (fen-phen). Therefore, the FDA approved Belviq, but they requested that a randomized, double-blind, placebo-controlled clinical trial be conducted to evaluate the potential risk of heart related problems associated with the drug. In this trial, which reviewed 12,000 patients over a 5 year period, more patients taking Belviq compared to those taking the placebo were diagnosed with cancer.
History of the Case
On January 14, 2020, the FDA issued a warning letter stating that Belviq may cause an increased risk of cancer, but that final conclusions are still uncertain. The FDA has promised to continue to evaluate the results of the clinical trial and communicate their final assessment of Belviq.
Injuries Related to Product
Cancers Possibly Linked to Belviq:
Interested in learning more about the Belviq lawsuit? … Continue
Gustafson, A., King, C., Rey, J. (2013) Lorcaserin (Belviq) A Selective Serotonin 5-HT2C Agonist In the Treatment of Obesity. Drug Forecast, 38, 9, 525-534… Continue